NASDAQ:ARRY - Array BioPharma Stock Price, Price Target & More

$14.09 -0.35 (-2.42 %)

(As of 04/22/2018 04:00 PM ET)

Previous Close$14.09

Today's Range$14.08 - $14.65

52-Week Range$6.73 - $18.78

Volume2.23 million shs

Average Volume2.44 million shs

Market Capitalization$2.93 billion

P/E Ratio-19.57

Dividend YieldN/A

Beta1.73

About Array BioPharma (NASDAQ:ARRY)

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:ARRY

CUSIP04269X10

Webwww.arraybiopharma.com

Phone303-381-6600

Debt

Debt-to-Equity Ratio0.39%

Current Ratio6.17%

Quick Ratio6.17%

Price-To-Earnings

Trailing P/E Ratio-19.57

Forward P/E Ratio-16.01

P/E GrowthN/A

Sales & Book Value

Annual Sales$150.85 million

Price / Sales19.39

Cash FlowN/A

Price / CashN/A

Book Value$0.07 per share

Price / Book201.29

Profitability

EPS (Most Recent Fiscal Year)($0.72)

Net Income$-116,810,000.00

Net Margins-98.51%

Return on Equity-107.79%

Return on Assets-36.51%

Miscellaneous

Employees209

Outstanding Shares207,640,000

How to Become a New Pot Stock Millionaire

Array BioPharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array BioPharma's earnings last quarter?

Array BioPharma (NASDAQ:ARRY) announced its earnings results on Tuesday, February, 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.06. The biopharmaceutical company had revenue of $42.21 million for the quarter, compared to the consensus estimate of $26.81 million. Array BioPharma had a negative return on equity of 107.79% and a negative net margin of 98.51%. The firm's revenue for the quarter was down 5.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.14) EPS. View Array BioPharma's Earnings History.

When is Array BioPharma's next earnings date?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Array BioPharma.

What price target have analysts set for ARRY?

8 analysts have issued 12 month price objectives for Array BioPharma's stock. Their predictions range from $13.00 to $23.00. On average, they anticipate Array BioPharma's stock price to reach $17.25 in the next year. View Analyst Ratings for Array BioPharma.

What are Wall Street analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (2/9/2018)
2. Cantor Fitzgerald analysts commented, "ARRY and ASLAN (NC) have updated a 2011 agreement for varlitinib, a pan-HER2 inhibitor, providing nearer term cash to ARRY in exchange for commercialization rights (the prior agreement covered development)." (1/3/2018)

Who are some of Array BioPharma's key competitors?

Some companies that are related to Array BioPharma include Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS) and Amicus Therapeutics (FOLD).

Who are Array BioPharma's key executives?

Array BioPharma's management team includes the folowing people:

Mr. Ron Squarer, Chief Exec. Officer and Director (Age 51)
Mr. Jason Haddock, Chief Financial Officer (Age 48)
Mr. Andrew R. Robbins, Chief Operating Officer (Age 42)
Dr. Victor Sandor M.D., C.M, Chief Medical Officer (Age 52)
Dr. Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 59)

Has Array BioPharma been receiving favorable news coverage?

Media coverage about ARRY stock has trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Array BioPharma earned a media sentiment score of 0.16 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Array BioPharma?

Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array BioPharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $14.09.

How big of a company is Array BioPharma?

Array BioPharma has a market capitalization of $2.93 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Array BioPharma employs 209 workers across the globe.

How can I contact Array BioPharma?

Array BioPharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]

MarketBeat Community Rating for Array BioPharma (ARRY)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		337 (Vote Outperform)
Underperform Votes:		177 (Vote Underperform)
Total Votes:		514

MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Array BioPharma (NASDAQ:ARRY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Array BioPharma in the last 12 months. Their average twelve-month price target is $17.25, suggesting that the stock has a possible upside of 22.43%. The high price target for ARRY is $23.00 and the low price target for ARRY is $13.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	2.86
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$17.25	$17.25	$15.25	$13.8571
Price Target Upside:	22.43% upside	1.71% downside	16.06% upside	22.74% upside

Array BioPharma (NASDAQ:ARRY) Consensus Price Target History

Price Target History for Array BioPharma (NASDAQ:ARRY)

Array BioPharma (NASDAQ:ARRY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/7/2018	Leerink Swann	Boost Price Target	Outperform -> Outperform	$19.00 -> $20.00	Low
2/7/2018	Stifel Nicolaus	Boost Price Target	Buy -> Buy	$20.00 -> $23.00	High
2/6/2018	SunTrust Banks	Reiterated Rating	Buy	$20.00	Low
1/21/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$15.00	Low
12/22/2017	Jefferies Group	Boost Price Target	Buy	$13.00	N/A
9/20/2017	Piper Jaffray	Reiterated Rating	Overweight	$14.00 -> $18.00	Low
9/11/2017	Cowen	Reiterated Rating	Outperform	$14.00 -> $15.00	High
9/11/2017	JPMorgan Chase	Reiterated Rating	Buy	$14.00	High

(Data available from 4/22/2016 forward)

Array BioPharma (NASDAQ:ARRY) Earnings History and Estimates Chart

Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)

Array BioPharma (NASDAQ:ARRY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.97)
2019 EPS Consensus Estimate: ($0.71)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.31)	($0.19)	($0.25)
Q2 2018	2	($0.32)	($0.18)	($0.25)
Q3 2018	3	($0.27)	($0.18)	($0.21)
Q4 2018	3	($0.29)	($0.21)	($0.26)
Q1 2019	1	($0.24)	($0.24)	($0.24)
Q2 2019	1	($0.01)	($0.01)	($0.01)
Q3 2019	1	($0.23)	($0.23)	($0.23)
Q4 2019	1	($0.23)	($0.23)	($0.23)

Array BioPharma (NASDAQ ARRY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018		($0.22)					N/A
2/6/2018	Q2 2018	($0.23)	($0.17)	$26.81 million	$42.21 million	View	N/A
10/31/2017	Q1 2018	($0.22)	($0.22)	$33.74 million	$29.75 million	View	N/A
8/9/2017	Q4 2017	($0.21)	($0.17)	$28.64 million	$33.80 million	View	Listen
5/10/2017	Q3 2017	($0.1610)	($0.21)	$38.28 million	$33.28 million	View	N/A
2/9/2017	Q2 2017	($0.18)	($0.14)	$31.90 million	$44.50 million	View	Listen
11/1/2016	Q117	($0.16)	($0.20)	$32.47 million	$39.30 million	View	Listen
8/4/2016	Q416	($0.14)	($0.17)	$41.51 million	$43.20 million	View	Listen
5/3/2016	Q316	($0.12)	($0.16)	$30.35 million	$43.00 million	View	Listen
2/2/2016	Q216	($0.06)	($0.17)	$32.70 million	$35.40 million	View	Listen
11/4/2015	Q116	($0.18)	($0.15)	$14.02 million	$16.20 million	View	Listen
8/3/2015	Q415	($0.16)	($0.09)	$10.29 million	$12.30 million	View	Listen
5/4/2015	Q315	($0.01)	$0.37	$6.00 million	$6.60 million	View	Listen
2/3/2015	Q215	($0.20)	($0.06)	$10.20 million	$26.92 million	View	Listen
11/4/2014	Q115	($0.22)	($0.21)	$6.35 million	$6.07 million	View	Listen
8/12/2014	Q414	($0.23)	($0.22)	$8.10 million	$6.00 million	View	Listen
4/29/2014	Q314	($0.21)	($0.20)	$9.40 million	$7.80 million	View	Listen
2/4/2014	Q214	($0.16)	($0.13)	$13.49 million	$14.10 million	View	Listen
10/31/2013	Q114	($0.18)	($0.13)	$11.20 million	$14.20 million	View	Listen
8/7/2013	Q4 2013	($0.13)	($0.06)	$16.13 million	$25.40 million	View	Listen
5/6/2013	Q3 2013	($0.14)	($0.19)	$14.54 million	$10.00 million	View	Listen
2/4/2013	Q2 2013	($0.14)	($0.10)	$16.52 million	$18.40 million	View	Listen
10/29/2012	Q113	($0.15)	($0.13)	$16.70 million	$15.80 million	View	N/A
8/13/2012		($0.11)	($0.09)			View	N/A
4/30/2012		($0.16)	($0.11)			View	N/A
1/30/2012		($0.12)	($0.06)			View	N/A
10/31/2011	Q1 2012	($0.19)	($0.06)			View	N/A
8/8/2011	Q4 2011	($0.27)	($0.17)			View	N/A
5/2/2011		($0.25)	($0.20)			View	N/A
1/31/2011		($0.28)	($0.23)			View	N/A
11/8/2010	Q1 2011	($0.28)	($0.20)			View	N/A
8/9/2010	Q4 2010	($0.32)	($0.30)			View	N/A
5/3/2010	Q3 2010	($0.34)	($0.30)			View	N/A
2/1/2010	Q2 2010	($0.55)	($0.44)			View	N/A
11/2/2009	Q1 2010	($0.55)	($0.52)			View	N/A
8/10/2009	Q4 2009	($0.55)	($0.55)			View	N/A
5/4/2009	Q3 2009	($0.58)	($0.55)			View	N/A
2/2/2009	Q2 2009	($0.65)	($0.57)			View	N/A
11/3/2008	Q1 2009	($0.65)	($0.63)			View	N/A
8/11/2008	Q4 2008	($0.63)	($0.68)			View	N/A
5/5/2008	Q3 2008	($0.51)	($0.51)			View	N/A
2/4/2008	Q2 2008	($0.46)	($0.43)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Array BioPharma (NASDAQ:ARRY) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Array BioPharma (NASDAQ ARRY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 96.38%

Insider Trading History for Array BioPharma (NASDAQ:ARRY)

Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)

Array BioPharma (NASDAQ ARRY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/18/2018	Lunsen Gil J Van	Director	Sell	21,500	$15.19	$326,585.00	24,797
4/3/2018	Victor Sandor	Insider	Sell	8,689	$15.35	$133,376.15
3/21/2018	Lunsen Gil J Van	Director	Sell	21,500	$16.76	$360,340.00	26,297
3/9/2018	Victor Sandor	Insider	Sell	156,016	$17.71	$2,763,043.36
2/21/2018	Lunsen Gil J Van	Director	Sell	21,500	$17.16	$368,940.00	32,797
2/9/2018	Charles M Baum	Director	Sell	50,000	$16.90	$845,000.00	35,000
1/17/2018	Lunsen Gil J Van	Director	Sell	21,500	$12.94	$278,210.00	34,297
1/16/2018	Jason Haddock	CFO	Sell	7,500	$13.73	$102,975.00	36,368
12/19/2017	Ron Squarer	CEO	Sell	819,671	$10.86	$8,901,627.06
12/18/2017	Andrew R. Robbins	COO	Sell	282,874	$10.72	$3,032,409.28
9/29/2017	Kyle Lefkoff	Director	Sell	38,865	$12.31	$478,428.15	51,585
3/28/2017	Charles M Baum	Director	Sell	25,000	$9.27	$231,750.00	30,000
9/28/2016	Redmile Group, Llc	Major Shareholder	Sell	2,492,578	$6.36	$15,852,796.08
9/15/2016	Redmile Group, Llc	Major Shareholder	Buy	400,000	$3.51	$1,404,000.00
1/20/2016	Redmile Group, Llc	Major Shareholder	Buy	300,000	$3.19	$957,000.00
1/12/2016	Redmile Group, Llc	Major Shareholder	Buy	75,000	$3.60	$270,000.00
1/11/2016	Redmile Group, Llc	Major Shareholder	Buy	925,000	$3.67	$3,394,750.00
10/1/2015	Redmile Group, Llc	Major Shareholder	Buy	782,592	$4.58	$3,584,271.36
8/25/2015	Redmile Group, Llc	Major Shareholder	Buy	790,000	$5.38	$4,250,200.00
8/10/2015	Redmile Group, Llc	Major Shareholder	Buy	1,048,993	$5.80	$6,084,159.40
3/3/2015	Kyle Lefkoff	Director	Sell	70,000	$8.00	$560,000.00
3/2/2015	Andrews R Robbins	SVP	Sell	21,576	$8.25	$178,002.00
3/2/2015	Ron Squarer	CEO	Sell	40,000	$8.25	$330,000.00
9/16/2013	Liam Ratcliffe	Director	Sell	1,673,172	$6.08	$10,172,885.76
9/6/2013	Liam Ratcliffe	Director	Sell	577,286	$5.79	$3,342,485.94
8/2/2013	John R Moore	VP	Sell	75,384	$7.02	$529,195.68
7/23/2013	John R Moore	VP	Sell	5,000	$6.50	$32,500.00

(Data available from 1/1/2013 forward)

Array BioPharma (NASDAQ ARRY) News Headlines

Source:

Date	Headline
	$32.07 Million in Sales Expected for Array Biopharma Inc (ARRY) This Quarter www.americanbankingnews.com - April 21 at 4:52 AM
	Array Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.22 Per Share www.americanbankingnews.com - April 19 at 5:39 AM
	Array Biopharma Inc (ARRY) Director Lunsen Gil J. Van Sells 21,500 Shares www.americanbankingnews.com - April 18 at 7:28 PM
	Array Biopharma (ARRY) Downgraded by BidaskClub to "Strong Sell" www.americanbankingnews.com - April 18 at 6:54 PM
	Array Biopharma (ARRY) Given Buy Rating at Cantor Fitzgerald www.americanbankingnews.com - April 17 at 5:25 PM
	See what the IHS Markit Score report has to say about Array Biopharma Inc. finance.yahoo.com - April 16 at 9:57 AM
	Array Biopharma Inc (ARRY) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - April 12 at 8:49 AM
	Stifel Nicolaus Reaffirms "Buy" Rating for Array Biopharma (ARRY) www.americanbankingnews.com - April 11 at 3:24 PM
	Array Biopharma (ARRY) Given a $13.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - April 11 at 12:43 AM
	Array Biopharma (ARRY) Earns "Buy" Rating from Piper Jaffray www.americanbankingnews.com - April 10 at 10:31 PM
	Array Biopharma Sees Unusually High Options Volume (ARRY) www.americanbankingnews.com - April 6 at 8:03 AM
	Brokerages Expect Array Biopharma Inc (ARRY) Will Announce Quarterly Sales of $32.07 Million www.americanbankingnews.com - April 4 at 4:37 AM
	Array Biopharma Inc (ARRY) Insider Victor Sandor Sells 8,689 Shares www.americanbankingnews.com - April 3 at 10:46 PM
	ValuEngine Upgrades Array Biopharma (ARRY) to "Buy" www.americanbankingnews.com - April 3 at 7:34 PM
	Is There An Opportunity With Array BioPharma Inc’s (NASDAQ:ARRY) 32% Undervaluation? finance.yahoo.com - April 3 at 10:18 AM
	Array Biopharma's (ARRY) "Buy" Rating Reiterated at Stifel Nicolaus www.americanbankingnews.com - April 2 at 3:42 PM
	Cantor Fitzgerald Analysts Give Array Biopharma (ARRY) a $15.00 Price Target www.americanbankingnews.com - March 30 at 10:36 PM
	Array Biopharma (ARRY) Upgraded to Hold at BidaskClub www.americanbankingnews.com - March 29 at 11:17 AM
	Leerink Swann Upgrades Array Biopharma (ARRY) to Outperform www.americanbankingnews.com - March 27 at 10:01 AM
	Today’s Research Reports on Trending Tickers: Geron Corporation and Array BioPharma Inc. finance.yahoo.com - March 26 at 10:50 AM
	Array Biopharma (ARRY) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - March 23 at 11:20 PM
	Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology finance.yahoo.com - March 22 at 9:52 AM
	Insider Selling: Array Biopharma Inc (ARRY) Director Sells 21,500 Shares of Stock www.americanbankingnews.com - March 21 at 7:32 PM
	$31.65 Million in Sales Expected for Array Biopharma Inc (ARRY) This Quarter www.americanbankingnews.com - March 18 at 11:56 AM
	Array Biopharma Inc (ARRY) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - March 18 at 8:54 AM
	Head-To-Head Contrast: Array Biopharma (ARRY) vs. Neuroderm (NDRM) www.americanbankingnews.com - March 17 at 7:24 PM
	Array Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.21 Per Share www.americanbankingnews.com - March 16 at 3:08 AM
	Array Biopharma Inc (ARRY) Insider Sells $2,763,043.36 in Stock www.americanbankingnews.com - March 9 at 6:14 PM
	Array BioPharma To Present At The Cowen 38th Annual Healthcare Conference finance.yahoo.com - March 5 at 4:18 PM
	Wells Fargo & Company MN Sells 192,639 Shares of Array Biopharma Inc (ARRY) www.americanbankingnews.com - March 5 at 3:26 PM
	State of Wisconsin Investment Board Has $2.16 Million Holdings in Array Biopharma Inc (ARRY) www.americanbankingnews.com - March 4 at 9:32 AM
	Swiss National Bank Has $3.95 Million Holdings in Array Biopharma Inc (ARRY) www.americanbankingnews.com - March 4 at 8:23 AM
	UBS Asset Management Americas Inc. Buys 1,338,377 Shares of Array Biopharma Inc (ARRY) www.americanbankingnews.com - March 2 at 7:52 PM
	EAM Investors LLC Cuts Stake in Array Biopharma Inc (ARRY) www.americanbankingnews.com - March 2 at 12:57 PM
	Hudson Bay Capital Management LP Grows Stake in Array Biopharma Inc (ARRY) www.americanbankingnews.com - March 2 at 12:49 PM
	Array Biopharma Inc (ARRY) Short Interest Update www.americanbankingnews.com - March 2 at 2:40 AM
	Array Biopharma Inc (ARRY) Shares Bought by Schwab Charles Investment Management Inc. www.americanbankingnews.com - March 1 at 5:15 PM
	118,158 Shares in Array Biopharma Inc (ARRY) Purchased by X Square Capital LLC www.americanbankingnews.com - February 27 at 2:35 PM
	Analysts Anticipate Array Biopharma Inc (ARRY) to Post -$0.21 Earnings Per Share www.americanbankingnews.com - February 27 at 3:26 AM
	Array Biopharma Inc (ARRY) Director Sells $368,940.00 in Stock www.americanbankingnews.com - February 23 at 6:32 PM
	Array BioPharma Inc. (ARRY) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - February 21 at 10:50 AM
	Array BioPharma (ARRY) Price Target Raised to $20.00 www.americanbankingnews.com - February 19 at 9:40 PM
	Options Traders Expect Huge Moves in Array BioPharma (ARRY) Stock finance.yahoo.com - February 16 at 9:30 AM
	Zacks.com highlights: Cinemark Holdings, Hasbro, Enova International, Array BioPharma and TechTarget finance.yahoo.com - February 14 at 3:22 PM
	Array BioPharma Inc. (ARRY) Director Charles M. Baum Sells 50,000 Shares www.americanbankingnews.com - February 12 at 6:32 PM
	$31.65 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter www.americanbankingnews.com - February 12 at 6:18 AM
	Zacks: Brokerages Anticipate Array BioPharma Inc. (ARRY) to Announce -$0.22 EPS www.americanbankingnews.com - February 10 at 9:44 AM
	Short Interest in Array BioPharma Inc. (ARRY) Decreases By 15.4% www.americanbankingnews.com - February 10 at 2:02 AM
	Array BioPharma (ARRY) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - February 9 at 6:10 PM
	Q3 2018 Earnings Forecast for Array BioPharma Inc. Issued By Leerink Swann (ARRY) www.americanbankingnews.com - February 9 at 11:36 AM

Array BioPharma (NASDAQ:ARRY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Array BioPharma (NASDAQ:ARRY) Income Statement, Balance Sheet and Cash Flow Statement

Array BioPharma (NASDAQ ARRY) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff